"Until then, the only way to save lives is to mask, socially distance, test, trace and isolate. Feinglass, M.D., M.P.H., chief medical officer for Beckman Coulter. "While vaccines are coming, it will take time before everyone is able to receive their shot," said Shamiram R. The organization can deliver 25 million tests per month, and the assay separates sample collection and processing, enabling test providers to leverage the existing infrastructure and workflows.Īdditionally, Beckman Coulter's new assay is priced at $4 to all healthcare providers, including public and private institutions, governments and non-profits to enable frequent testing. Beckman Coulter's SARS CoV-2 Antigen test is designed to address these challenges. While several point of care (POC) antigen tests are now available to help increase testing beyond current levels, POC tests come with workflow challenges when scaled to large patient populations. Currently, only about 1.8 million RT-PCR tests are performed daily in the U.S. New York University economist Paul Romer suggested recently that number could be significantly higher 3. Results of the Beckman Coulter antigen test can be delivered in as little as 30 minutes on the organizations' immunoassay analyzers, including the DxI 800, a high-throughput analyzer capable of processing 200 samples per hour.Īccording to the Rockefeller Foundation, 4.3 million COVID-19 tests per day are recommended to help minimize infection spread and save lives 2. Additionally, the assay and has a limit of detection of 33 TCID50/mL, which is 2 to 200 times lower and therefore more sensitive than the reported limits of detection for most of the available point-of-care (POC) antigen tests 1. The Access SARS-CoV-2 Antigen assay has proven 93% Positive Percent Agreement (PPA) within seven days post symptom onset and 100% Negative Percent Agreement (NPA). Beckman Coulter's assay is offered to healthcare providers at $4, making reliable and frequent mass testing affordable